Atomi Financial Group Inc. Has $413,000 Stake in Boston Scientific Co. (NYSE:BSX)

Atomi Financial Group Inc. lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 23.9% during the first quarter, Holdings Channel reports. The fund owned 6,030 shares of the medical equipment provider’s stock after buying an additional 1,163 shares during the quarter. Atomi Financial Group Inc.’s holdings in Boston Scientific were worth $413,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of BSX. Massmutual Trust Co. FSB ADV raised its position in shares of Boston Scientific by 35.4% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 3,409 shares of the medical equipment provider’s stock worth $197,000 after purchasing an additional 892 shares during the period. First Hawaiian Bank increased its position in shares of Boston Scientific by 4.5% during the fourth quarter. First Hawaiian Bank now owns 23,065 shares of the medical equipment provider’s stock worth $1,333,000 after acquiring an additional 1,000 shares in the last quarter. Wedmont Private Capital raised its holdings in shares of Boston Scientific by 13.4% in the 4th quarter. Wedmont Private Capital now owns 14,295 shares of the medical equipment provider’s stock worth $835,000 after acquiring an additional 1,684 shares during the last quarter. WBH Advisory Inc. bought a new position in Boston Scientific in the 4th quarter valued at about $206,000. Finally, Nordea Investment Management AB boosted its stake in Boston Scientific by 6.0% during the 4th quarter. Nordea Investment Management AB now owns 100,912 shares of the medical equipment provider’s stock valued at $5,870,000 after purchasing an additional 5,747 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

BSX stock traded up $0.45 during midday trading on Monday, reaching $78.14. 4,288,334 shares of the company’s stock traded hands, compared to its average volume of 6,145,189. The firm has a market capitalization of $114.64 billion, a PE ratio of 65.60, a price-to-earnings-growth ratio of 2.67 and a beta of 0.78. The company has a 50-day moving average price of $75.81 and a two-hundred day moving average price of $69.14. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $78.98. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. The business had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. As a group, equities analysts anticipate that Boston Scientific Co. will post 2.32 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BSX. Citigroup raised their target price on Boston Scientific from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. BTIG Research lifted their price objective on shares of Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a report on Monday. Morgan Stanley upped their target price on shares of Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday. Evercore ISI boosted their price target on shares of Boston Scientific from $78.00 to $81.00 and gave the stock an “outperform” rating in a report on Tuesday, July 2nd. Finally, UBS Group upped their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $80.71.

Insider Activity

In related news, EVP John Bradley Sorenson sold 17,587 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the sale, the executive vice president now owns 50,638 shares in the company, valued at $3,620,617. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the sale, the executive vice president now owns 42,908 shares in the company, valued at approximately $3,316,788.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the transaction, the executive vice president now owns 50,638 shares of the company’s stock, valued at $3,620,617. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,259 shares of company stock worth $5,344,014. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.